Skip To Main Content

Genentech co-pay programs provide financial assistance to eligible commercially insured patients to help with their co-pays, co-insurance, or other out-of-pocket (OOP) costs.

  • ALECENSA® (alectinib)
  • AVASTIN® (bevacizumab)
  • COLUMVI (glofitamab-gxbm)
  • COTELLIC® (cobimetinib)
  • ERIVEDGE® (vismodegib)
  • GAVRETO® (pralsetinib)
  • GAZYVA® (obinutuzumab)
  • HERCEPTIN® (trastuzumab)
  • HERCEPTIN HYLECTA (trastuzumab and hyaluronidase-oysk)
  • KADCYLA® (ado-trastuzumab emtansine)
  • LUNSUMIO (mosunetuzumab-axgb)
  • PERJETA® (pertuzumab)
  • PHESGO (pertuzumab, trastuzumab, and hyaluronidase- zzxf) injection, for subcutaneous use
  • POLIVY (polatuzumab vedotin-piiq)
  • RITUXAN® (rituximab)
  • RITUXAN HYCELA® (rituximab/hyaluronidase human)
  • ROZLYTREK (entrectinib)
  • TECENTRIQ® (atezolizumab)
  • VENCLEXTA® (venetoclax tablets)
  • ZELBORAF® (vemurafenib)
  • LUCENTIS® (ranibizumab injection)
  • SUSVIMO (ranibizumab injection)
  • VABYSMO (faricimab-svoa)

Eligibility criteria apply. Not valid for patients using federal or state government programs to pay for their medicine and/or administration of their Genentech medicine. Patients must be taking the Genentech medicine for an FDA-approved indication. Please visit the Co-pay Program website for the full list of Terms and Conditions.